Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
Why lifespans are more variable among blacks than whites in the U.S.

Eliminating health disparities between races is a goal of many groups and organizations, but a team of sociologists suggests that finding the reasons for the differences in the timing of black and white deaths may be trickier than once thought. Interventions to reduce this disparity may be more effective if they target sex, as well as race. "With regard to policy, our results indicate the importance of sex-specific intervention to reduce racial disparities," the researchers said. "In the case of HIV/AIDS, for example, there is greater potential for significant reduction of the racial gap when men are targeted. The opposite is true for heart disease and diabetes, where interventions focused on women are more likely to narrow the gap."

Published
17 December 2014
From
Science Daily
Issue Brief: Achieving undetectable: what questions remain in scaling-up HIV virologic treatment monitoring?

Although the majority of developing countries do not yet offer viral load testing on a routine basis, the use of HIV viral load monitoring is rapidly gathering pace in most developing countries. Which questions remain in further scaling up this gold standard for HIV treatment monitoring in these countries? Médecins Sans Frontières (MSF) is releasing Achieving Undetectable, the latest in a series of issue briefs and reports on access to viral load monitoring in resource-limited settings.

Published
15 December 2014
From
MSF
Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”

Published
12 December 2014
From
Chimicles & Tikellis press release
How San Francisco Is Getting to Zero On HIV

San Francisco is already making progress when it comes to HIV prevention, treatment and retention. In 2006, San Francisco had 517 new HIV cases; by 2013, that number dropped to 359, a 30 percent decrease. The number of deaths almost halved between 2006 and 2013, going from 327 to 182. Additionally, compared to the United States, San Francisco is faring better in multiple aspects of the HIV care continuum: in 2012, 82 percent of HIV positive individuals in the U.S. were aware of their status; in San Francisco, that number was 94 percent.

Published
11 December 2014
From
Huffington Post
Sophisticated HIV diagnostics adapted for remote areas

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

Published
10 December 2014
From
Science Daily
PEPFAR’s ‘Global Pediatric ARV Commitment-To-Action’ Aims To Improve Drug Access

Since the start of President Obama’s Administration, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has achieved a four-fold increase and is now providing 7.7 million people with life-saving antiretroviral (ARV) treatment worldwide. Despite this, only 1 in 4 of the 3.2 million children living with HIV/AIDS worldwide are today receiving treatment.

Published
09 December 2014
From
US Department of State
European HIV response "falling behind" as Eastern European epidemic grows

HIV diagnoses have increased by 80% in the European region since 2004, and three quarters of new HIV diagnoses in the European region are occurring in Eastern

Published
05 December 2014
By
Keith Alcorn
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries

The license being granted to Mylan extends to 112 countries, which together account for more than 30 million people living with HIV, representing 84% of those infected globally.

Published
04 December 2014
From
Mylan press release
South Africa: Should HIV Testing Become a Standard Medical Procedure?

Knowing your status is the key to ending the Aids pandemic but still too few South Africans take the step to get tested for HIV. A report in the Mail & Guardian this week less than a third of the country's 35-million sexually active people get tested for HIV annually.

Published
03 December 2014
From
AllAfrica.com
Over $1 billion saved by 2028 through Medicines Patent Pool licensing agreements

Since 2010, UNITAID’s investments in the MPP have yielded 2.6 times the value of its funding through such licensing deals. Between 2010 and 2028, this return on investment is projected to generate between $1.18 - $1.4 billion in savings due to price reductions through generic product manufacturing of key HIV medicines.

Published
02 December 2014
From
UNITAID
← First12345...83Next →

Filter by country